Who are Intravenous immune globulin G's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): IVIG infusion, Intravenous ImmuneGlobulin, Placebo and IVIG.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-immune-globulin-g.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Intravenous immune globulin G — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous immune globulin G (Intravenous immune globulin G) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunoglobulin replacement therapy / Immunomodulator. Area: Immunology / Hematology.

marketed Immunoglobulin replacement therapy / Immunomodulator Multiple (polyclonal IgG antibodies targeting various pathogens and self-antigens) Immunology / Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous immune globulin G (Intravenous immune globulin G) — Rutgers, The State University of New Jersey. Intravenous immune globulin G (IVIG) provides passive immunity by delivering pooled immunoglobulin G antibodies from multiple donors to boost immune function and modulate inflammatory responses.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intravenous immune globulin G TARGET	Intravenous immune globulin G	Rutgers, The State University of New Jersey	marketed	Immunoglobulin replacement therapy / Immunomodulator	Multiple (polyclonal IgG antibodies targeting various pathogens and self-antigens)
IVIG infusion	IVIG infusion	McMaster University	phase 3	Immunoglobulin replacement therapy / Immunomodulator	Multiple (Fc receptors, complement system, pathogen-specific antigens)
Intravenous ImmuneGlobulin	Intravenous ImmuneGlobulin	University Health Network, Toronto	phase 3	Immunoglobulin replacement therapy / Immunomodulator	Multiple (IgG antibodies, Fc receptors, complement system)
Placebo and IVIG	Placebo and IVIG	The Hospital for Sick Children	phase 3	Immunoglobulin replacement therapy / Immunomodulator	Multiple (Fc receptors, complement system, pathogenic antibodies)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunoglobulin replacement therapy / Immunomodulator class)

McMaster University · 1 drug in this class
Rutgers, The State University of New Jersey · 1 drug in this class
The Hospital for Sick Children · 1 drug in this class
University Health Network, Toronto · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous immune globulin G — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-immune-globulin-g. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab